[Chemotherapy in metastasizing prostate carcinoma].
Seventeen patients with metastasized hormone-resistant prostate cancer were treated between January 1986 and October 1989 with combination chemotherapy at the Department of Urology, University of Würzburg Medical School. In 1 of the 17 patients a complete remission lasting 4 months was observed. In 3 patients a partial remission was noted, and in 5 others stable disease for an average of 6.8 months occurred. Tumor progression was seen in 7 patients. In all 16 evaluable cases palliation of tumor pain was achieved with this kind of treatment. The role of chemotherapy in the treatment of metastasized prostate cancer is discussed.
Heimbach
D
D
Urologische Klinik und Poliklinik, Universität Würzburg.
Wirth
M
M
Frohmüller
H
H
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis
D000970:Antineoplastic Agents; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D008727:Methotrexate
Chemotherapie beim metastasierten Prostatakarzinom.